These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35176144)

  • 1. Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies.
    van Putten EHP; Kleijn A; van Beusechem VW; Noske D; Lamers CHJ; de Goede AL; Idema S; Hoefnagel D; Kloezeman JJ; Fueyo J; Lang FF; Teunissen CE; Vernhout RM; Bakker C; Gerritsen W; Curiel DT; Vulto A; Lamfers MLM; Dirven CMF
    Clin Cancer Res; 2022 Apr; 28(8):1572-1585. PubMed ID: 35176144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.
    van den Bossche WBL; Kleijn A; Teunissen CE; Voerman JSA; Teodosio C; Noske DP; van Dongen JJM; Dirven CMF; Lamfers MLM
    Neuro Oncol; 2018 Oct; 20(11):1494-1504. PubMed ID: 29796615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity.
    Kleijn A; Kloezeman J; Treffers-Westerlaken E; Fulci G; Leenstra S; Dirven C; Debets R; Lamfers M
    PLoS One; 2014; 9(5):e97495. PubMed ID: 24866126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells.
    Berghauser Pont LM; Kleijn A; Kloezeman JJ; van den Bossche W; Kaufmann JK; de Vrij J; Leenstra S; Dirven CM; Lamfers ML
    PLoS One; 2015; 10(5):e0127058. PubMed ID: 25993039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic concentrations of anti-epileptic drugs do not inhibit the activity of the oncolytic adenovirus Delta24-RGD in malignant glioma.
    de Jonge J; Berghauser Pont LM; Idema S; Kloezeman JJ; Noske D; Dirven CM; Lamfers ML
    J Gene Med; 2013; 15(3-4):134-41. PubMed ID: 23606319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer.
    Kim KH; Dmitriev IP; Saddekni S; Kashentseva EA; Harris RD; Aurigemma R; Bae S; Singh KP; Siegal GP; Curiel DT; Alvarez RD
    Gynecol Oncol; 2013 Sep; 130(3):518-24. PubMed ID: 23756180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma.
    Lang FF; Conrad C; Gomez-Manzano C; Yung WKA; Sawaya R; Weinberg JS; Prabhu SS; Rao G; Fuller GN; Aldape KD; Gumin J; Vence LM; Wistuba I; Rodriguez-Canales J; Villalobos PA; Dirven CMF; Tejada S; Valle RD; Alonso MM; Ewald B; Peterkin JJ; Tufaro F; Fueyo J
    J Clin Oncol; 2018 May; 36(14):1419-1427. PubMed ID: 29432077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Locally-delivered T-cell-derived cellular vehicles efficiently track and deliver adenovirus delta24-RGD to infiltrating glioma.
    Balvers RK; Belcaid Z; van den Hengel SK; Kloezeman J; de Vrij J; Wakimoto H; Hoeben RC; Debets R; Leenstra S; Dirven C; Lamfers ML
    Viruses; 2014 Aug; 6(8):3080-96. PubMed ID: 25118638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer.
    Page JG; Tian B; Schweikart K; Tomaszewski J; Harris R; Broadt T; Polley-Nelson J; Noker PE; Wang M; Makhija S; Aurigemma R; Curiel DT; Alvarez RD
    Am J Obstet Gynecol; 2007 Apr; 196(4):389.e1-9; discussion 389.e9-10. PubMed ID: 17403430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients.
    Li JL; Liu HL; Zhang XR; Xu JP; Hu WK; Liang M; Chen SY; Hu F; Chu DT
    Gene Ther; 2009 Mar; 16(3):376-82. PubMed ID: 19092859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas.
    Yong RL; Shinojima N; Fueyo J; Gumin J; Vecil GG; Marini FC; Bogler O; Andreeff M; Lang FF
    Cancer Res; 2009 Dec; 69(23):8932-40. PubMed ID: 19920199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The oncolytic adenovirus Δ24-RGD in combination with cisplatin exerts a potent anti-osteosarcoma activity.
    Martinez-Velez N; Xipell E; Jauregui P; Zalacain M; Marrodan L; Zandueta C; Vera B; Urquiza L; Sierrasesúmaga L; Julián MS; Toledo G; Fueyo J; Gomez-Manzano C; Torre W; Lecanda F; Patiño-García A; Alonso MM
    J Bone Miner Res; 2014 Oct; 29(10):2287-96. PubMed ID: 24737304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
    Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
    Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.
    Pesonen S; Diaconu I; Cerullo V; Escutenaire S; Raki M; Kangasniemi L; Nokisalmi P; Dotti G; Guse K; Laasonen L; Partanen K; Karli E; Haavisto E; Oksanen M; Karioja-Kallio A; Hannuksela P; Holm SL; Kauppinen S; Joensuu T; Kanerva A; Hemminki A
    Int J Cancer; 2012 Apr; 130(8):1937-47. PubMed ID: 21630267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy.
    Belcaid Z; Berrevoets C; Choi J; van Beelen E; Stavrakaki E; Pierson T; Kloezeman J; Routkevitch D; van der Kaaij M; van der Ploeg A; Mathios D; Sleijfer S; Dirven C; Lim M; Debets R; Lamfers MLM
    Neurooncol Adv; 2020; 2(1):vdaa011. PubMed ID: 32642679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delta-24 adenoviral therapy for glioblastoma: evolution from the bench to bedside and future considerations.
    Ene CI; Fueyo J; Lang FF
    Neurosurg Focus; 2021 Feb; 50(2):E6. PubMed ID: 33524949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases.
    Kimball KJ; Preuss MA; Barnes MN; Wang M; Siegal GP; Wan W; Kuo H; Saddekni S; Stockard CR; Grizzle WE; Harris RD; Aurigemma R; Curiel DT; Alvarez RD
    Clin Cancer Res; 2010 Nov; 16(21):5277-87. PubMed ID: 20978148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus.
    Phillips LM; Li S; Gumin J; Daou M; Ledbetter D; Yang J; Singh S; Parker Kerrigan BC; Hossain A; Yuan Y; Gomez-Manzano C; Fueyo J; Lang FF
    Neuro Oncol; 2021 Nov; 23(11):1911-1921. PubMed ID: 34059921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Oncolytic Adenovirus DNX-2401 Has Antitumor Activity in Glioblastoma.
    Cancer Discov; 2018 Apr; 8(4):382. PubMed ID: 29475886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice.
    Shin DH; Jiang H; Gillard AG; Kim D; Fan X; Singh SK; Nguyen TT; Sohoni SS; Lopez-Rivas AR; Parthasarathy A; Ene CI; Gumin J; Lang FF; Alonso MM; Gomez-Manzano C; Fueyo J
    Mol Ther; 2024 Mar; 32(3):722-733. PubMed ID: 38311852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.